MaritideAmgenInsurance Coverage Outlook

Formulary Tier

Expected: Tier 3 or Tier 4
Based on Wegovy/Zepbound patterns. Tier 4 (specialty) more likely initially, with potential Tier 3 placement if monthly dosing demonstrates superior adherence vs. weekly therapies. Copays: $100–$200 (Tier 3), $150–$500 (Tier 4).

Prior Authorization

Expected: Required
Your doctor will submit clinical documentation proving medical necessity: BMI ≥30 (or ≥27 with comorbidity), weight-related comorbidities, prior lifestyle interventions documented, no contraindications (history of pancreatitis, MEN2, medullary thyroid cancer).

Step Therapy

Possible but Less Likely
By 2029-2030, step therapy may be less restrictive than current landscape if real-world evidence shows early GLP-1 intervention improves outcomes. However, some plans may still require trying Wegovy or Zepbound first before approving "newer" maritide.

Monthly Dosing Advantage

Potential Coverage Benefit:
• Fewer pharmacy fills (12/year vs. 52) = lower dispensing fees for payers
• Easier adherence monitoring (12 refill checks vs. 52)
• Reduced prior auth renewal burden (annual vs. quarterly or semi-annual)
• May support preferred formulary placement vs. weekly alternatives

Obesity Indication (2029-2030 Projected Coverage)

Uncertain
By law, basic Medicare Part D coverage excludes drugs used for weight loss. The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers only Wegovy (injection and pill), Foundayo, and the Zepbound KwikPen for weight loss, for $50 per monthly fill with conditions; Maritide is not a Bridge drug, and CMS has not announced what replaces the Bridge after December 31, 2027. Maritide's monthly dosing may improve compliance monitoring, supporting coverage.

Cardiovascular Indication (If MARITIME-CV Is Positive)

Broad Coverage Expected
If maritide's MARITIME-CV trial demonstrates cardiovascular risk reduction (similar to semaglutide's SELECT trial), it could be covered under Medicare Part D for that cardiovascular use, subject to plan formularies and prior authorization.

Out-of-Pocket Costs (2029-2030 Projections)

Lower Than Current Landscape
Medicare negotiated pricing with manufacturers started in 2026. By 2029-2030, maritide may enter formularies with negotiated prices significantly below list price. Copays may range from $50-$200/month (vs. current $200-$500 for non-negotiated GLP-1s).

Important Evolution

2025-2026 vs. 2029-2030:
Current Medicare policies prohibit obesity-only coverage for most beneficiaries. By maritide's launch (2029-2030), obesity treatment may be mainstream Medicare coverage if legislative trends (Treat and Reduce Obesity Act) pass or CMS adds it to a program like the Medicare GLP-1 Bridge. Monthly dosing may be viewed favorably for Medicare adherence tracking.

States with GLP-1 Coverage (2025 Baseline)

13 states (as of January 2026)
These state Medicaid programs covered GLP-1s for obesity (per KFF). States change often: Medi-Cal stopped covering GLP-1s for weight loss on January 1, 2026, while NC Medicaid reinstated obesity GLP-1 coverage on December 12, 2025.

Monthly Dosing Cost Argument

May Improve State Coverage
State Medicaid programs cite high costs as a key exclusion rationale for weekly GLP-1s. Maritide's monthly dosing (12 fills/year vs. 52) may reduce per-patient costs and improve access arguments: fewer pharmacy fills = lower dispensing fees, easier compliance tracking, and reduced administrative burden.

Prior Authorization Requirements

Typically Required
States that cover GLP-1s usually require:
• BMI ≥30 (or ≥27 with comorbidity)
• 6-12 months documented weight-loss attempts
• Participation in behavioral weight-loss program
• Regular follow-up visits and adherence monitoring

2029-2030 Outlook

More States, Broader Coverage:
By maritide's launch, Medicaid GLP-1 coverage will likely be more widespread due to:
1. Accumulating evidence of cost savings (reduced diabetes, cardiovascular events)
2. Federal incentives or mandates (if obesity coverage becomes ACA-required preventive service)
3. Competitive pressure (neighboring states with coverage may drive expansion)
4. Monthly dosing cost advantages vs. weekly therapies

What It Is: Prior authorization requires your doctor to submit clinical documentation to your insurance company before they'll approve coverage. The insurer reviews your medical history, BMI, comorbidities, and prior treatments to determine if maritide is "medically necessary."

Why It Exists: Insurers use PA to control costs and ensure medications are used appropriately. For expensive medications like maritide, PA helps prevent off-label use and ensures patients meet clinical criteria.

How to Overcome:

• Work with your doctor to submit a complete PA form with all required documentation
• Include a detailed letter of medical necessity explaining why maritide is appropriate (e.g., monthly dosing improves adherence)
• Document your BMI, weight-related comorbidities (cardiovascular disease, diabetes, sleep apnea), and prior weight-loss attempts
• If denied, appeal immediately with additional supporting evidence
• Consider using Honest Care's appeal service to improve approval chances

What It Is: Step therapy requires you to try and fail less expensive treatments (like Wegovy or Zepbound) before your insurer will approve maritide. This can delay access by 3-6 months.

Why It Exists: Step therapy controls costs by ensuring patients start with lower-cost interventions. If those work, expensive newer medications aren't needed.

How to Overcome:

• Document prior treatment failures thoroughly (medications tried, duration, outcomes)
• Request a step therapy exception if you have contraindications to weekly injections (e.g., severe needle phobia, travel requirements)
• Demonstrate why monthly dosing is medically superior for you (e.g., adherence challenges with weekly therapies)
• Emphasize maritide's unique mechanism (GLP-1 agonist + GIP antagonist) vs. dual agonism if prior GLP-1s failed

What It Is: Quantity limits restrict how much medication you can receive per fill. For maritide, this may be less restrictive than weekly therapies since monthly dosing naturally limits quantity (12 fills/year vs. 52).

Why It Exists: Insurers use quantity limits to monitor high-cost medication use and reduce waste.

Maritide Advantage:

• Monthly dosing reduces quantity limit concerns vs. weekly therapies
• Fewer fills = less opportunity for overuse or diversion
• May support 90-day supplies (3 monthly doses) vs. 30-day only for weekly GLP-1s

What It Is: Some plans completely exclude obesity medications from coverage, meaning no amount of appeals will result in approval.

Why It Exists: Employers and insurers may exclude entire drug classes (like obesity medications) to control costs.

How to Overcome:

• Check your plan's formulary BEFORE maritide launches to confirm obesity medications aren't excluded
• If excluded, appeal to your employer's HR department during open enrollment (2028-2029)
• Consider switching plans during open enrollment to one that covers obesity medications
• Explore manufacturer savings programs (Amgen will likely offer copay assistance)
• If you have cardiovascular disease or diabetes, emphasize those indications rather than weight loss alone